Search clinical trials for: AZD5363
Total 35 results
-
National University Hospital, SingaporeRecruiting
-
University of NottinghamAstraZeneca; Cancer Research UK; National Cancer Research NetworkCompleted
-
AstraZenecaCompletedSafety and Tolerability, | Advanced Solid Malignancy, | Pharmacokinetics, Pharmacodynamics, | Tumour Response,United Kingdom, Netherlands
-
Memorial Sloan Kettering Cancer CenterCompletedBreast Cancer | Prostate Cancer | Advanced Solid TumorsUnited States
-
Royal Marsden NHS Foundation TrustAstraZeneca; Institute of Cancer Research, United KingdomCompleted
-
AstraZenecaCompletedAdvanced Solid Tumor | Advanced Solid MalignancyJapan
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
National Taiwan University HospitalRecruitingMetastatic Breast Cancer | Premenopausal Breast Cancer | ER Positive Breast CancerTaiwan
-
AstraZenecaRecruitingTriple Negative Breast NeoplasmsUnited States, Korea, Republic of, Canada, Taiwan, United Kingdom, Poland
-
Institute of Cancer Research, United KingdomRoyal Marsden NHS Foundation TrustRecruitingAdvanced Breast CancerUnited Kingdom
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); GlaxoSmithKline; Genentech, Inc.; Brain Science...RecruitingIntracranial Meningioma | Recurrent Meningioma | NF2 Gene MutationUnited States
-
UNICANCERAstraZeneca; Fondation ARCActive, not recruiting
-
UNICANCERAstraZeneca; Intergroupe Francophone de Cancerologie Thoracique; Fondation ARCCompletedNon-small Cell Lung Cancer MetastaticFrance
-
George Sakoulas, MDOctapharmaCompleted
-
Queen Mary University of LondonAstraZeneca; Cancer Research UKActive, not recruitingMetastatic Breast CancerKorea, Republic of, United Kingdom, Hungary, Georgia, France, Romania
-
University Hospital Southampton NHS Foundation...AstraZeneca; Cancer Research UKCompletedProstate CancerUnited Kingdom
-
Institute of Cancer Research, United KingdomRoyal Marsden NHS Foundation TrustUnknownAdenocarcinoma of the ProstateUnited Kingdom
-
M.D. Anderson Cancer CenterRecruitingChondrosarcoma | Advanced Malignant Solid Neoplasm | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous... and other conditionsUnited States
-
AstraZenecaDaiichi Sankyo Co., Ltd.; Daiichi Sankyo Company, LimitedActive, not recruitingMetastatic Breast CancerBelgium, United States, Taiwan, Korea, Republic of, Brazil, Russian Federation, Canada, Australia, France, Mexico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast... and other conditionsUnited States
-
AstraZenecaActive, not recruitingTriple Negative Breast NeoplasmsUnited States, Spain, Sweden, Taiwan, Thailand, Vietnam, Turkey, Russian Federation, France, Korea, Republic of, United Kingdom, Brazil, Czechia, Hungary, India, Japan, Mexico, Peru, Philippines, Poland, China, Malaysia, Canada, Portugal and more
-
AstraZenecaCompletedMetastatic Castrate-Resistant Prostate Cancer (mCRPC), | Efficacy, | Safety and Tolerability, | Pharmacokinetics, | Pharmacodynamics, | Tumour Response.United Kingdom, United States
-
AstraZenecaParexelCompleted
-
OHSU Knight Cancer InstituteAstraZeneca; Oregon Health and Science UniversityRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingGlioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditionsUnited States, Puerto Rico, Guam
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingEndometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Endometrial Adenocarcinoma | Endometrioid AdenocarcinomaUnited States, Canada
-
University of BirminghamPfizer; AstraZeneca; Mirati Therapeutics Inc.; Cancer Research UK; Experimental Cancer...Active, not recruitingAdenocarcinoma | Carcinoma, Squamous Cell | Non-Small Cell Lung CancerUnited Kingdom
-
AstraZenecaActive, not recruitingCervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 PositiveUnited States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
-
Joseph Paul EderDana-Farber Cancer Institute; The Cleveland Clinic; Vanderbilt-Ingram Cancer...Terminated
-
Velindre NHS TrustAstraZeneca; Cardiff and Vale University Health Board; Covance; Cenduit LLCActive, not recruitingEstrogen Receptor Positive Breast CancerUnited Kingdom
-
Samsung Medical CenterCompleted
-
Samsung Medical CenterTerminatedAdvanced Gastric AdenocarcinomaKorea, Republic of
-
AstraZenecaQuotient SciencesCompleted
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria